|
Abnormal behavior
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In a longitudinal subanalysis-cohort, FABP5 levels were stable over a two-month period with no behavioral changes (<i>p</i> = 0.099).
|
28490445 |
2017 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CRABP-II- and FABP5-independent responsiveness of human glioblastoma cells to all-trans retinoic acid.
|
25797252 |
2015 |
|
Age related macular degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated fatty acid-binding protein 5 (FABP5) downregulation in the RPE/choroidal complex in a mouse model of aging and early age-related macular degeneration.
|
19434059 |
2010 |
|
Agnosia for Pain
|
0.020 |
Biomarker
|
disease |
BEFREE |
α-Truxillic acid monoesters (TAMEs) constitute a class of inhibitors targeting fatty acid binding protein 5 (FABP5), whose inhibition produces analgesia in animal models.
|
31237895 |
2019 |
|
Agnosia for Pain
|
0.020 |
Biomarker
|
disease |
BEFREE |
Previous work indicates that systemically administered FABP5 inhibitors produce analgesia in models of inflammatory pain.
|
28326944 |
2017 |
|
Alzheimer's Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
DHA supplementation has been shown to be beneficial in various mouse models of AD, and therefore, the aim of this study was to determine whether DHA has the potential to up-regulate the BBB expression of FABP5, thereby enhancing its own uptake into the brain.
|
29582413 |
2018 |
|
Alzheimer's Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
This study reports a 42.1 ± 12.6% decrease in the BBB transport of <sup>14</sup> C-DHA in 8-month-old AD transgenic mice (APPswe,PSEN1∆E9) relative to wild-type mice, associated with a 34.5 ± 6.7% reduction in FABP5 expression in isolated brain capillaries of AD mice.
|
29105065 |
2018 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
Alternatively, reexpression of endogenous CRABP2 could be enabled in FABP5(high)CRABP2(null) PDAC lines by exposure to decitabine and trichostatin A, thereby relieving epigenetic silencing of the CRABP2 gene promoter.
|
22010213 |
2012 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
FABP5 is associated with increased subclinical atherosclerosis.
|
27055964 |
2016 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, in contrast to FABP4, circulating FABP5 is associated with decreased CEC and carotid atherosclerosis, suggesting that FABP5 level is a regulatory factor of CEC and a potential biomarker for residual risk of atherosclerosis.
|
28303004 |
2017 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
In particular, genetic deficiency and small molecule-mediated inhibition of FABP4 (also known as aP2) and FABP5 can potently improve glucose homeostasis and reduce atherosclerosis in mouse models.
|
26260145 |
2015 |
|
Astrocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CRABP-II and FABP5 were expressed to varying degrees by the 84-astrocytoma cases examined.
|
25797252 |
2015 |
|
Atherogenic dyslipidaemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our aim was to examine the role of circulating FABP5 levels and its main SNPs in atherogenic dyslipidemia (AD) assessed by 2D-Nuclear Magnetic Resonance (NMR) and related metabolic and inflammation markers.
|
27055964 |
2016 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
In particular, genetic deficiency and small molecule-mediated inhibition of FABP4 (also known as aP2) and FABP5 can potently improve glucose homeostasis and reduce atherosclerosis in mouse models.
|
26260145 |
2015 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, in contrast to FABP4, circulating FABP5 is associated with decreased CEC and carotid atherosclerosis, suggesting that FABP5 level is a regulatory factor of CEC and a potential biomarker for residual risk of atherosclerosis.
|
28303004 |
2017 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
FABP5 is associated with increased subclinical atherosclerosis.
|
27055964 |
2016 |
|
Autism Spectrum Disorders
|
0.010 |
Biomarker
|
disease |
BEFREE |
In postmortem brains, we detected altered mRNA expression levels of FABP5 in schizophrenia, and of FABP7 in ASD and altered FABP5 in peripheral lymphocytes.
|
25027319 |
2014 |
|
Autoimmune thyroid disease (AITD)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Monocytes of 24% of AITD and 50% of latent autoimmune diabetes of adults (LADA) patients shared an inflammatory fingerprint consisting of the set of 24 genes of the PDE4B, FABP5, and overlapping gene sets.
|
20147583 |
2010 |
|
Bacterial Infections
|
0.020 |
Biomarker
|
group |
BEFREE |
Our study indicates that FABP5 exerts immunomodulatory functions in the airway epithelium against CS exposure and subsequent bacterial infection through its modulation of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-γ activity.
|
23349676 |
2013 |
|
Bacterial Infections
|
0.020 |
AlteredExpression
|
group |
BEFREE |
These data demonstrate that cigarette smoke interferes with FABP5 expression in response to bacterial infection.
|
28542209 |
2017 |
|
Biliary Tract Cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
FABP5 appears to play a role in malignant progression in large BTCs.
|
31432248 |
2020 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The expression and subcellular distribution of two RA-binding proteins, FABP5 and CRABP2, has already been shown to play critical roles in breast cancer cell response to RA.
|
26142905 |
2015 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
FABP5 knockdown in breast cancer cell lines demonstrates a correlation between FABP5 levels and growth response to RA.
|
21356353 |
2011 |
|
Breast Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Further, immunohistochemistry was performed to detect differential expression of ATGL and FABP5 in breast cancer tissue sections.
|
29914512 |
2018 |
|
Breast Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
In this study, the inhibitory effects of ATPR on the proliferation, invasion, and migration of breast cancer (BC) cells, and the relationship between ATPR and the expression of the intracellular lipid-binding proteins CRABP2 and FABP5 were investigated.
|
29731607 |
2018 |